Tau and transgenic animal models

Brain Research Reviews

Volumn 35, Issue 3, 2001, Pages 266-286

  Götz, Jürgen ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Frontotemporal dementia; Neurofibrillary tangle; Phosphorylation; Tau; Tauopathy; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CASEIN KINASE I; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; ISOPROTEIN; MICROTUBULE ASSOCIATED PROTEIN 1; MICROTUBULE ASSOCIATED PROTEIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEIN KINASE (CALCIUM,CALMODULIN) II; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL MODEL; CELL FUNCTION; CHROMOSOME 17; CORTICOBASAL DEGENERATION; DEMENTIA; DISEASE ASSOCIATION; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; KNOCKOUT MOUSE; LAMPREY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROFILAMENT; NEUROPATHOLOGY; NONHUMAN; PARKINSONISM; PEPTIDE SYNTHESIS; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BRAIN; DEMENTIA; DISEASE MODELS, ANIMAL; HUMANS; NEURODEGENERATIVE DISEASES; TAU PROTEINS;

EID: 0034992339     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(01)00055-8     Document Type: Review

References (209)

1. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5
2. Gliding movement of and bidirectional transport along single native microtubules from squid axoplasm: Evidence for an active role of microtubules in cytoplasmic transport
3. Does dysregulation of the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease?
4. Structure and novel exons of the human tau gene
5. Teratocarcinomas and human embryology: Pluripotent human EC cell lines. Review article
6. Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: Morphology and its relationship to tau aggregation
7. Paired helical filament-like phosphorylation of tau, deposition of beta/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A
8. Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene
9. Quantitative neurohistological features of frontotemporal degeneration
10. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease
11. Identification of 3′UTR region implicated in tau mRNA stabilization in neuronal cells
12. Association of an extended haplotype in the tau gene with progressive supranuclear palsy
13. Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration
14. A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L)
15. Diagnostic approaches to Alzheimer's disease
16. Alzheimer's disease: Neurodevelopment converges with neurodegeneration
17. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads
18. Staging of Alzheimer's disease-related neurofibrillary changes
19. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease
20. Pick's disease. Anatomo-clinical point of view
21. Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgenes
22. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders
23. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease
24. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease
25. AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease
26. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau
27. Neurofibrillary pathology in progressive supranuclear palsy (PSP)
28. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
29. Glial inclusions in CNS degenerative diseases
30. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17
31. Genetic evidence for the involvement of tau in progressive supranuclear palsy
32. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: A mouse model of amyotrophic lateral sclerosis
33. Primary structure of high molecular weight tau present in the peripheral nervous system
34. Microtubule-associated protein 2c reorganizes both microtubules and microfilaments into distinct cytological structures in an actin-binding protein-280-deficient melanoma cell line
35. Reelin is a ligand for lipoprotein receptors
36. Familial dementia caused by polymerization of mutant neuroserpin
37. Wnt signaling function in Alzheimer's disease
38. Familial progressive supranuclear palsy. Description of a pedigree and review of the literature
39. Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration
40. Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation
41. A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy
42. Missense tau mutations identified in FTDP-17 have a small effect on tau-microtubule interactions
43. Correlations of synaptic and pathological markers with cognition of the elderly
44. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state
45. Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcineurin and phosphatase-2A
46. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements
47. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes
48. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism
49. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: Implications for Alzheimer's disease
50. Neuronal abnormalities in microtubule-associated protein 1B mutant mice
51. Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: Differentiation from progressive supranuclear palsy
52. Neuropathologic overlap of progressive supranuclear palsy. Pick's disease and corticobasal degeneration
53. Immature human NT2 cells grafted into mouse brain differentiate into neuronal and glial cell types
54. The structure of divalent cation-induced aggregates of PIP2 and their alteration by gelsolin and tau
55. Pick and focal brain atrophy
56. Frontotemporal dementia and parkinsonism linked to chromosome 17: A consensus conference
57. Structure of tau protein and assembly into paired helical filaments
58. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein
59. Tau phosphorylation in brain slices: Pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase
60. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity
61. Cyclin-dependent kinase 5-deficient mice demonstrate novel developmental arrest in cerebral cortex
62. Filamentous nerve cell inclusions in neurodegenerative diseases: Tauopathies and alpha-synucleinopathies
63. p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease
64. Tau mutations cause frontotemporal dementias
65. Expression of separate isoforms of human tau protein: Correlation with the tau pattern in brain and effects on tubulin polymerization
66. Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments
67. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: Identification of phosphorylation sites in tau protein
68. The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development
69. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205
70. Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system
71. Tau gene mutation in familial progressive subcortical gliosis
72. Molecular dissection of the paired helical filament
73. Dephosphorylation of microtubule-associated protein tau by protein phosphatase-1 and -2C and its implication in Alzheimer disease
74. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease
75. Structural and functional differences between 3-repeat and 4-repeat tau isoforms. Implications for normal tau function and the onset of neurodegenerative disease
76. Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau
77. In vivo analysis of wild-type and FTDP-17 tau transgenic mice
78. Tau filament formation in transgenic mice expressing p301l tau
79. Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit Cα
80. Distinct role of protein phosphatase 2A subunit c-alpha in the regulation of E-cadherin and beta-catenin during development
81. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform
82. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau
83. Human tau filaments induce microtubule and synapse loss in an in vivo model of neurofibrillary degenerative disease
84. Extensive dendritic sprouting induced by close axotomy of central neurons in the lamprey
85. Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy
86. Human tau becomes phosphorylated and forms filamentous deposits when overexpressed in lamprey central neurons in situ
87. The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
88. Altered microtubule organization in small-calibre axons of mice lacking tau protein
89. Okadaic acid induces hyperphosphorylated forms of tau protein in human brain slices
90. Abnormally phosphorylated protein tau in the cortex of aged individuals of various mammalian orders
91. Alzheimer-like changes in microtubule-associated protein Tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation
92. Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging
93. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation
94. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - Inverse correlation with dementia severity
95. Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease - Correlation with degree of cognitive impairment
96. Quantitative neuropathologic analysis of Pick's disease cases: Cortical distribution of Pick bodies and coexistence with Alzheimer's disease
97. Correlative memory deficits, A-beta elevation, and amyloid plaques in transgenic mice
98. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins
99. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF
100. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
101. Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice
102. Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments
103. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform
104. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice
105. Reversible in vivo phosphorylation of tau induced by okadaic acid and by unspecific brain lesion in rat
106. Tau complexes with phospholipase C-gamma in situ
107. Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease
108. Altered conformation of recombinant frontotemporal dementia-17 mutant tau proteins
109. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease
110. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: A study in Japan
111. Cytoskeletal changes in the brains of mice lacking calcineurin A alpha
112. Familial frontotemporal dementia with ubiquitin-positive, tau-negative inclusions
113. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia
114. Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease
115. Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration
116. Tau interacts with src-family non-receptor tyrosine kinases
117. Expression of tau protein in non-neuronal cells: Microtubule binding and stabilization
118. Neurotoxicity induces cleavage of p35 to p25 by calpain
119. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein
120. Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein Tau
121. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes
122. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease
123. Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation
124. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)
125. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders
126. Competition for microtubule-binding with dual expression of tau missense and splice isoforms
127. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex
128. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments
129. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes
130. Spinal cord neurofibrillary tangles of Guamanian amyotrophic lateral sclerosis and parkinsonism-dementia complex: An immunohistochemical study
131. Developmental changes of cyclin dependent kinase 5 subcellular localization in the rat cerebellum
132. The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases
133. Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23) transfected cells
134. Tau pathology in a family with dementia and a P301L mutation in tau
135. Interaction of the tail domain of high molecular weight subunits of neurofilaments with the COOH-terminal region of tubulin and its regulation by tau protein kinase II
136. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain
137. Tau and apo E in CSF: Potential aid for discriminating Alzheimer's disease from other dementias
138. The pool of map kinase associated with microtubules is small but constitutively active
139. Signal transduction through prion protein
140. Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits
141. Accelerated filament formation from tau protein with specific FTDP-17 missense mutations
142. KIF1B, a novel microtubule plus end-directed monomeric motor protein for transport of mitochondria
143. Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells
144. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
145. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death
146. Familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene
147. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
148. Corticonigral degeneration with neuronal achromasia and basal neurofibrillary tangles
149. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration
150. Tau is a candidate gene for chromosome 17 frontotemporal dementia
151. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein
152. Corticodentatonigral degeneration with neuronal achromasia
153. Autosomal dominant dementia with widespread neurofibrillary tangles
154. Association of mitogen-activated protein kinase with the microtubule cytoskeleton
155. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: Differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta
156. Corticobasal degeneration. A clinical study of 36 cases
157. Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients
158. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands
159. SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis
160. Tau epitopes in spinal cord neurofibrillary lesions in Chamorros of Guam
161. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments
162. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure
163. Alzheimer's disease: Genotypes, phenotypes, and treatments
164. Proteins of the CNR family are multiple receptors for Reelin
165. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: Tau pathologies with exclusively exon 10 isoforms
166. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau
167. The neuropathology of chromosome 17-linked dementia
168. Phosphorylation of tau protein by casein kinase-1 converts it to an abnormal Alzheimer-like state
169. Ser-262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK
170. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
171. A novel pool of protein phosphatase 2A is associated with microtubules and is regulated during the cell cycle
172. Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A
173. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies
174. FTDP-17: An early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation
175. Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau
176. Familial multiple system tauopathy with presenile dementia: A disease with abundant neuronal and glial tau filaments
177. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
178. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein
179. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice
180. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
181. Familial presenile dementia with psychosis associated with cortical neurofibrillary tangles and degeneration of the amygdala
182. Delayed development of nervous system in mice homozygous for disrupted microtubule-associated protein 1B (MAP1B) gene
183. The regulation of phosphorylation of tau in SY5Y neuroblastoma cells: The role of protein phosphatases
184. Somatodendritic localization of phosphorylated tau in neonatal and adult rat cerebral cortex
185. Differential axonal transport of soluble and insoluble tau in the rat sciatic nerve
186. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice
187. A new case of frontotemporal dementia and parkinsonism resulting from an intron 10 +3-splice site mutation in the tau gene: Clinical and pathological features
188. Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles
189. Neurons derived from a human teratocarcinoma cell line establish molecular and structural polarity following transplantation into the rodent brain
190. Organelle, bead, and microtubule translocations promoted by soluble factors from the squid giant axon
191. Phenotypic variation in hereditary frontotemporal dementia with tau mutations
192. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization
193. Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells
194. Proteolytic processing of the Alzheimer disease-associated presenilin-1 generates an in vivo substrate for protein kinase C
195. Phosphorylation of the beta-amyloid precursor protein at the cell surface by ectocasein kinases 1 and 2
196. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B
197. Calpain and caspase: Can you tell the difference?
198. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22
199. Dissecting the behaviour of transgenic mice: Is it the mutation, the genetic background, or the environment?
200. Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration
201. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease
202. Alpha-synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam
203. A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration
204. FTDP-17 tau mutations decrease the susceptibility of tau to calpain I digestion
205. Fibrillogenesis of tau: Insights from tau missense mutations in FTDP-17
206. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation
207. Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia
208. Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth